vs

Side-by-side financial comparison of AEMETIS, INC (AMTX) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $43.3M, roughly 1.8× AEMETIS, INC). On growth, AEMETIS, INC posted the faster year-over-year revenue change (-7.9% vs -16.8%). Over the past eight quarters, Bioceres Crop Solutions Corp.'s revenue compounded faster (-8.4% CAGR vs -22.8%).

Aemetis, Inc. is a renewable fuels and sustainable biochemicals producer operating across North America and India. Its core products include low-carbon ethanol, renewable natural gas and biodiesel, serving transportation, industrial and agricultural sectors with decarbonization solutions for commercial clients.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

AMTX vs BIOX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.8× larger
BIOX
$77.6M
$43.3M
AMTX
Growing faster (revenue YoY)
AMTX
AMTX
+9.0% gap
AMTX
-7.9%
-16.8%
BIOX
Faster 2-yr revenue CAGR
BIOX
BIOX
Annualised
BIOX
-8.4%
-22.8%
AMTX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AMTX
AMTX
BIOX
BIOX
Revenue
$43.3M
$77.6M
Net Profit
$-7.4M
Gross Margin
17.8%
46.8%
Operating Margin
-5.7%
9.3%
Net Margin
-9.6%
Revenue YoY
-7.9%
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.03
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMTX
AMTX
BIOX
BIOX
Q4 25
$43.3M
Q3 25
$59.2M
$77.6M
Q2 25
$52.2M
Q1 25
$42.9M
$60.6M
Q4 24
$47.0M
$98.8M
Q3 24
$81.4M
$93.3M
Q2 24
$66.6M
Q1 24
$72.6M
$84.0M
Net Profit
AMTX
AMTX
BIOX
BIOX
Q4 25
Q3 25
$-23.7M
$-7.4M
Q2 25
$-23.4M
Q1 25
$-24.5M
$-1.6M
Q4 24
$605.2K
Q3 24
$-17.9M
$-6.2M
Q2 24
$-29.2M
Q1 24
$-24.2M
$9.8M
Gross Margin
AMTX
AMTX
BIOX
BIOX
Q4 25
17.8%
Q3 25
-0.1%
46.8%
Q2 25
-6.4%
Q1 25
-11.8%
39.4%
Q4 24
-4.3%
42.0%
Q3 24
4.8%
40.2%
Q2 24
-2.7%
Q1 24
-0.8%
50.8%
Operating Margin
AMTX
AMTX
BIOX
BIOX
Q4 25
-5.7%
Q3 25
-14.4%
9.3%
Q2 25
-20.4%
Q1 25
-36.3%
1.5%
Q4 24
-28.7%
14.5%
Q3 24
-4.8%
2.5%
Q2 24
-20.4%
Q1 24
-13.0%
15.7%
Net Margin
AMTX
AMTX
BIOX
BIOX
Q4 25
Q3 25
-40.1%
-9.6%
Q2 25
-44.8%
Q1 25
-57.2%
-2.6%
Q4 24
0.6%
Q3 24
-22.0%
-6.6%
Q2 24
-43.8%
Q1 24
-33.4%
11.6%
EPS (diluted)
AMTX
AMTX
BIOX
BIOX
Q4 25
$-0.03
Q3 25
$-0.37
$-0.12
Q2 25
$-0.41
Q1 25
$-0.47
$-0.02
Q4 24
$-0.29
$0.00
Q3 24
$-0.38
$-0.10
Q2 24
$-0.66
Q1 24
$-0.58
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMTX
AMTX
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$4.9M
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$-306.8M
$288.3M
Total Assets
$259.8M
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMTX
AMTX
BIOX
BIOX
Q4 25
$4.9M
Q3 25
$5.6M
$15.5M
Q2 25
$1.6M
Q1 25
$499.0K
$38.5M
Q4 24
$898.0K
$29.2M
Q3 24
$296.0K
$32.3M
Q2 24
$234.0K
Q1 24
$1.6M
$16.4M
Total Debt
AMTX
AMTX
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$338.1M
Q3 24
$322.2M
Q2 24
$309.0M
Q1 24
$307.2M
Stockholders' Equity
AMTX
AMTX
BIOX
BIOX
Q4 25
$-306.8M
Q3 25
$-304.9M
$288.3M
Q2 25
$-289.3M
Q1 25
$-280.7M
$345.0M
Q4 24
$-263.9M
$346.3M
Q3 24
$-258.9M
$346.0M
Q2 24
$-249.0M
Q1 24
$-232.1M
$348.5M
Total Assets
AMTX
AMTX
BIOX
BIOX
Q4 25
$259.8M
Q3 25
$241.1M
$734.9M
Q2 25
$240.0M
Q1 25
$242.5M
$798.2M
Q4 24
$259.3M
$835.2M
Q3 24
$259.3M
$827.3M
Q2 24
$259.3M
Q1 24
$259.3M
$836.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMTX
AMTX
BIOX
BIOX
Operating Cash FlowLast quarter
$5.8M
$14.4M
Free Cash FlowOCF − Capex
$-10.8M
FCF MarginFCF / Revenue
-24.9%
Capex IntensityCapex / Revenue
38.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMTX
AMTX
BIOX
BIOX
Q4 25
$5.8M
Q3 25
$3.1M
$14.4M
Q2 25
$-5.7M
Q1 25
$160.0K
$23.3M
Q4 24
$-12.6M
$-5.4M
Q3 24
$-5.0M
$5.2M
Q2 24
$-5.1M
Q1 24
$-10.3M
$-17.4M
Free Cash Flow
AMTX
AMTX
BIOX
BIOX
Q4 25
$-10.8M
Q3 25
$-1.0M
Q2 25
$-9.3M
Q1 25
$-1.7M
Q4 24
$-19.4M
Q3 24
$-9.5M
Q2 24
$-10.5M
Q1 24
$-13.9M
FCF Margin
AMTX
AMTX
BIOX
BIOX
Q4 25
-24.9%
Q3 25
-1.7%
Q2 25
-17.7%
Q1 25
-3.9%
Q4 24
-41.2%
Q3 24
-11.6%
Q2 24
-15.8%
Q1 24
-19.1%
Capex Intensity
AMTX
AMTX
BIOX
BIOX
Q4 25
38.2%
Q3 25
6.9%
Q2 25
6.7%
Q1 25
4.3%
Q4 24
14.4%
Q3 24
5.5%
Q2 24
8.1%
Q1 24
4.9%
Cash Conversion
AMTX
AMTX
BIOX
BIOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMTX
AMTX

Ethanol Sales$28.8M66%
Wet Distillers Grains$6.8M16%
California Dairy Renewable Natural Gas$5.2M12%
Other$1.8M4%

BIOX
BIOX

Segment breakdown not available.

Related Comparisons